GIST Cancer UK News

Please see the latest news, research and findings below...

regorafenib (Stivarga®) is accepted for use within NHS Scotland – 2015

regorafenib has been approved in Scotland for treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who have progressed on or are intolerant to prior treatment with imatinib and sunitinib. This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of regorafenib and is contingent […]

Continue reading

GIST Support UK’s #100000voices Campaign 2015

March 2015 Jayne Bressington, vice chair of GIST Support UK (, talks to BBC Radio Humberside about the government’s plans to stop funding for the rare cancer drug Regorafenib. The petition to stop these cuts has gained 100,000+ signatures and we are now calling on everyone to write to their local parliamentary candidates ahead of […]

Continue reading

Scottish Sarcoma Network – 2013

Patients who are interested, are welcome to attend any of the Sarcoma education days, which you can see on the Scottish Sarcoma Network website. Any patients that are interested in these days, or would be interested in extra support, find out about available services or need help with any concerns are encouraged to get […]

Continue reading

Pub Quiz in aid of Gist Support UK – 2013

The Pub Quiz on Oct 17 in Tooting was an absolutely fantastic evening and success. First and foremost, the biggest mention must go to Barbara’s sister Jan for putting together the event pretty much single-handedly by all accounts – even persuading her son to fly in from Moscow – that is serious fundraising for you! […]

Continue reading

GSUK helps to fund GIST research – 2012

On 20th August we were delighted to present our medical consultant, Professor Ian Judson, with a cheque for £20,000 to help support a new research project. Professor Judson plans to collect data on all the patients who are being or have been treated at the Royal Marsden Hospital, in order to study the correlation between […]

Continue reading

SMC approves adjuvant use of Imatinib – 2012

Imatinib (Glivec) has been accepted for restricted use within Scotland for certain high risk GIST adult patients. The SMC accepted that adjuvant imatinib for three years compared to one year significantly improved survival. However, this treatment has yet to be approved by NICE for England & Wales. Click here for full details from SMC.

Continue reading